Walgreens and Freenome Partner to Increase Diversity in Research

Walgreens and Freenome have established a collaborative partnership aimed at advancing clinical studies for Freenome's blood-based tests for early cancer detection. This multi-year relationship involves Walgreens leveraging its nationwide presence, patient insights, recruitment technology, and local infrastructure to engage diverse patient populations in Freenome's comprehensive research program on detecting multiple types of cancer.

To kickstart their collaboration, Walgreens will commence patient recruitment across various communities for Freenome's Sanderson Study. This study intends to assess the effectiveness of blood-based early detection tests for multiple types of cancer. Leveraging Curebase's platform, Walgreens will implement targeted outreach initiatives, such as text messages, emails, and in-person consultations at their pharmacies, to reach potentially eligible patients and their caregivers from diverse backgrounds. Once a pre-screening process is completed, eligible patients will have the opportunity to enrol in the study.

Walgreens' healthcare providers will then facilitate a single blood draw at one of the company's clinical trial locations, and participants will receive a telehealth follow-up one year after their involvement. Through its clinical study partner network, which includes Walgreens, the Sanderson Study aims to enrol around 8,000 participants in total.

Click here to read the original news story.